xevinapant (Debio 1143)

Selected Solid Tumors

Debio 1143 is a potent, orally available, inhibitor of IAPs (Inhibitor of Apoptosis Proteins) that displays immunomodulatory properties making it a natural candidate for combination with Immune Checkpoint Inhibitors. In addition, like other members of the class, Debio 1143 promotes apoptosis of cancer cells by mimicking the activity of the natural Second Mitochondrial-derived Activator of Caspases (SMAC). Through this dual mode of action, Debio 1143 is expected to improve cancer patient treatment outcomes in combination with immunotherapy, chemotherapy and/or radiotherapy respectively investigated in NSCLC, H&N cancer and Ovarian Cancer.

Click here for more information about our Expanded Access (EA) policy for Debio 1143

SMARTPLUS Trial information

SMARTPLUS-106 is a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in the following indications:Gastrointestinal cancersGynecologic cancersSmall cell lung cancers and Head & neck cancers

Clinical trials

Press releases

All Press Releases